Laekna (HKG:2105) advanced its obesity drug LAE123 to pre-clinical candidate declaration and has commenced an IND-enabling study of the drug for treating severe diseases, according to a Wednesday filing with the Hong Kong bourse.
LAE123 is a strong ActRIIA and ActRIIB blocker with superior potency in cell-based reporter gene assays (RGA) aimed at finding cures for severe diseases, such as pulmonary arterial hypertension and spinal muscular atrophy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。